AM Rx vs GetRelief Rx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AM Rx
Best for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully)Starting at $25/mo
GetRelief Rx
Best for buyers specifically seeking sublingual (non-injectable) compounded GLP-1 drops who understand the bioavailability trade-offs and lack of human PK data for this formulationStarting at $179/mo
Side-by-Side Comparison
| Feature | AM Rx | GetRelief Rx |
|---|---|---|
| Overall Score | 5.9/10 | ✓6.1/10 |
| Starting Price | ✓$25/mo | $179/mo |
| Editorial Rating | 3 ★ /5 | ✓3.1 ★ /5 |
| Features | ✓6 features | 5 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 2 warnings | ✓None |
Pros & Cons
AM Rx
Pros
- ✓Insurance coordination for brand-name GLP-1s — as low as $25/mo
- ✓All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- ✓HSA and FSA accepted
- ✓Video visits available (not just async) with providers averaging 10+ years experience
- ✓Compounded semaglutide from $151/mo quarterly
Cons
- ✗Active FTC/DOJ lawsuit for deceptive billing and subscription practices (ROSCA violations)
- ✗Two FDA warning letters (Sept 2025, Feb 2026) for misbranding compounded GLP-1 products
- ✗Novo Nordisk false advertising lawsuit (Aug 2025)
- ✗Parent entity Zealthy has BBB D- rating with 2,370+ complaints
- ✗Trustpilot 2.0/5 — 85% one-star reviews citing billing disputes and unreachable support
- ✗No visible LegitScript certification or PCAB accreditation
- ✗No named pharmacy partners — compounding source not disclosed
- ✗No FDA compounding disclaimer on the website
- ✗State availability not publicly disclosed
- ✗Founder Kyle Robertson previously ran Cerebral, which settled FTC charges for similar practices
- ✗Same corporate entity (FitRX LLC) as Zealthy and FitRx — shares regulatory history
GetRelief Rx
Pros
- ✓Both compounded semaglutide and tirzepatide available at publicly displayed pricing — no login wall to see costs
- ✓BBB accredited with A rating (March 2026); NPI 1306697834 is independently verifiable
- ✓Free online assessment — no upfront consultation fee before prescribing decision
Cons
- ✗SUBLINGUAL ONLY — no injectable option. Sublingual compounded semaglutide and tirzepatide have NOT been tested in human pharmacokinetic studies; mouse models suggest 5-8x higher doses needed to match subcutaneous bioavailability. Readers should understand this is NOT the same delivery method studied in STEP/SURMOUNT trials.
- ✗REGULATORY FLAG: GetReliefRX continues to offer compounded tirzepatide as of April 2026, after FDA ended enforcement discretion for tirzepatide compounding (March 19, 2025 for 503B, April 22, 2025 for 503A). The legal basis may be state-level exemptions, but this is not publicly disclosed on the site.
- ✗No LegitScript, PCAB, or NABP certifications identified — BBB accreditation is not a pharmacy-specific compliance credential
- ✗Prescriber credentials are described generically as 'licensed clinicians' without specifying MD/DO/NP/PA breakdown
Our Verdict
GetRelief Rx edges out AM Rx with a higher overall score of 6.1/10 and is particularly strong for buyers specifically seeking sublingual (non-injectable) compounded GLP-1 drops who understand the bioavailability trade-offs and lack of human PK data for this formulation. AM Rx remains a solid alternative, especially if you're looking for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.